From GlobeNewswire: 2025-05-31 08:05:00

Roche’s ItovebiTM (inavolisib)-based regimen has shown a 30% reduced risk of death in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer compared to standard treatment. This data was presented at the 2025 ASCO Annual Meeting and published in the NEJM. The regimen also doubled progression-free survival and delayed the need for chemotherapy. The regimen is approved in several countries and is under review in the EU. Further studies are ongoing to explore its benefits in other cancers. Itovebi targets a common mutation in breast cancer, providing a new treatment option for patients. A new study presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting shows that the ItovebiTM (inavolisib)-based regimen can reduce the risk of death by over 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer compared to other treatments. The PIK3CA mutation is found in around 40% of HR-positive advanced breast cancers and is linked to a poor prognosis. This advancement provides hope for people facing disease progression and side effects from treatment, highlighting the importance of ongoing research in breast cancer treatment. Roche has been at the forefront of breast cancer research for over 30 years, aiming to improve outcomes for those affected by the disease. With a focus on developing new approaches and biomarkers for different subtypes of breast cancer, Roche continues to make strides in personalized healthcare. Founded in Basel, Switzerland in 1896, Roche is the world’s largest biotechnology company and a leader in in-vitro diagnostics. Committed to sustainability and innovation, Roche strives to develop medicines and diagnostics that contribute to healthier lives. A study presented at the 2025 ASCO Annual Meeting showed that the ItovebiTM regimen reduced the risk of death by over 30% in individuals with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared to palbociclib and fulvestrant alone. The PIK3CA mutation is present in about 40% of HR-positive advanced breast cancers and is linked to a poor prognosis. The new data is published in the New England Journal of Medicine, highlighting the potential benefits of this treatment approach for a subset of breast cancer patients.



Read more at GlobeNewswire: New data show Roche’s Itovebi significantly extended